We have located links that may give you full text access.
INTRODUCTORY JOURNAL ARTICLE
RESEARCH SUPPORT, N.I.H., EXTRAMURAL
Monoclonal antibodies in lymphoma: the first decade.
Seminars in Hematology 2008 April
The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has significantly contributed to these improved therapeutic outcomes. This issue will explore the impact of monoclonal antibody therapy on outcome in indolent lymphoma, and detail how this improved outcome has changed clinical practice. Furthermore, the role of monoclonal antibodies in maintenance regimens and the main indications for radiolabeled antibodies will be discussed in detail. Finally, possible future developments in the field will be proposed, including the use of monoclonal antibodies in ablative transplantation and in the treatment of leukemias.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app